5 results on '"Wesley T. Beaulieu"'
Search Results
2. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy
- Author
-
Lee M. Jampol, Adam R. Glassman, Michael J. Elman, Andrew N. Antoszyk, Hani Salehi-Had, Wesley T. Beaulieu, Clement C Chow, Jennifer K. Sun, and Maureen G. Maguire
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Visual acuity ,genetic structures ,Recombinant Fusion Proteins ,medicine.medical_treatment ,Visual Acuity ,Angiogenesis Inhibitors ,Vitrectomy ,law.invention ,Randomized controlled trial ,law ,Interquartile range ,Ranibizumab ,Ophthalmology ,Post-hoc analysis ,Diabetes Mellitus ,medicine ,Humans ,Original Investigation ,Aflibercept ,Diabetic Retinopathy ,business.industry ,Diabetic retinopathy ,Middle Aged ,medicine.disease ,eye diseases ,Vitreous Hemorrhage ,Receptors, Vascular Endothelial Growth Factor ,Treatment Outcome ,Intravitreal Injections ,Vitreous hemorrhage ,Female ,sense organs ,medicine.symptom ,business ,medicine.drug - Abstract
IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic retinopathy (PDR), post hoc analyses may influence treatment choices. OBJECTIVE: To compare exploratory outcomes between treatment groups that may affect treatment choices for patients with vitreous hemorrhage due to PDR. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial conducted at 39 DRCR Retina Network sites included adults with vision loss due to PDR-related vitreous hemorrhage for whom vitrectomy was considered. Data were collected from November 2016 to January 2020. INTERVENTIONS: Random assignment to 4 monthly injections of aflibercept vs vitrectomy with PRP. Both groups could receive aflibercept or vitrectomy during follow-up based on protocol-specific criteria. MAIN OUTCOMES AND MEASURES: Visual acuity area under the curve (adjusted for baseline VA) and clearance of vitreous hemorrhage. RESULTS: A total of 205 eyes were included in the analysis (115 male [56%] and 90 [44%] female participants; mean [SD] age, 57 [11] years). Among 89 eyes with a baseline VA of 20/32 to 20/160 (47 receiving aflibercept, including 4 [9%] that had undergone vitrectomy; 42 undergoing vitrectomy, including 3 [7%] that had received aflibercept), the adjusted mean difference in VA letter score over 24 weeks between the aflibercept and vitrectomy groups was −4.3 (95% CI, −10.6 to 1.9) compared with −16.7 (95% CI, −24.4 to −9.1) among 59 eyes with baseline VA worse than 20/800 (P = .02 for interaction; 26 in the aflibercept group, including 6 [23%] that had undergone vitrectomy; 33 in the vitrectomy group, including 8 [24%] that had received aflibercept). In the full cohort, the median time to clearance of the initial vitreous hemorrhage was 36 (interquartile range [IQR], 24-52) weeks in the aflibercept group vs 4 (IQR, 4-4) weeks in the vitrectomy group (difference, 32 [95% CI, 20-32] weeks; P
- Published
- 2021
3. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Charles C. Wykoff, Neil M. Bressler, Lee M. Jampol, Wesley T. Beaulieu, Jennifer K. Sun, Carl W. Baker, Cynthia R. Stockdale, Omar S. Punjabi, and Adam R. Glassman
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Visual acuity ,genetic structures ,medicine.medical_treatment ,Recombinant Fusion Proteins ,Visual Acuity ,Angiogenesis Inhibitors ,Observation ,Macular Edema ,law.invention ,Randomized controlled trial ,Clinical Protocols ,Interquartile range ,law ,Ophthalmology ,medicine ,Humans ,Aflibercept ,Aged ,Original Investigation ,Diabetic Retinopathy ,Laser Coagulation ,business.industry ,Hazard ratio ,Diabetic retinopathy ,Middle Aged ,medicine.disease ,eye diseases ,Receptors, Vascular Endothelial Growth Factor ,Intravitreal Injections ,Female ,medicine.symptom ,business ,Laser coagulation ,Tomography, Optical Coherence ,Retinopathy ,medicine.drug ,Follow-Up Studies - Abstract
IMPORTANCE: Among eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity (VA), randomized clinical trial results showed no difference in VA loss between initial observation plus aflibercept only if VA decreased, initial focal/grid laser plus aflibercept only if VA decreased, or prompt aflibercept. Understanding the initial observation approach is relevant to patient management. OBJECTIVE: To assess the DRCR Retina Network protocol-defined approach and outcomes of initial observation with aflibercept only if VA worsened. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analyses of a randomized clinical trial of the DRCR Retina Network Protocol V that included 91 US and Canadian sites from November 2013 to September 2018. Participants were adults (n = 236) with type 1 or 2 diabetes, 1 study eye with CI-DME, and VA letter score at least 79 (Snellen equivalent, 20/25 or better) assigned to initial observation. Data were analyzed from March 2019 to November 2019. INTERVENTIONS: Initial observation and follow-up with aflibercept only for VA loss of at least 10 letters from baseline at 1 visit or 5 to 9 letters at 2 consecutive visits. Follow-up occurred at 8 weeks and then every 16 weeks unless VA or optical coherence tomography central subfield thickness worsened. MAIN OUTCOMES AND MEASURES: Whether individuals received aflibercept. RESULTS: Among 236 eyes in 236 individuals (149 [63%] male; median age, 60 years [interquartile range, 53-67 years]) randomly assigned to initial observation, 80 (34%) were treated with aflibercept during 2 years of follow-up. At 2 years, the median VA letter score was 86.0 (interquartile range, 89.0-81.0; median Snellen equivalent, 20/20 [20/16-20/25]). Receipt of aflibercept was more likely in eyes with baseline central subfield thickness at least 300 μm (Zeiss-Stratus equivalent) vs less than 300 μm (45% vs 26%; hazard ratio [HR], 1.98 [95% CI, 1.26-3.13], continuous P = .005), moderately severe nonproliferative diabetic retinopathy (Early Treatment Diabetic Retinopathy Study retinopathy severity level 47) and above vs moderate nonproliferative diabetic retinopathy (retinopathy severity level 43) and below (51% vs 27%; HR, 2.22 [95% CI, 1.42-3.47], ordinal P
- Published
- 2020
4. Interpreting Multiple Outcomes of Pupillary Light Reflex in Sport-Related Concussion in Adolescents
- Author
-
Adam R. Glassman and Wesley T. Beaulieu
- Subjects
medicine.medical_specialty ,Injury control ,business.industry ,Poison control ,Human factors and ergonomics ,Suicide prevention ,Occupational safety and health ,Sport related concussion ,Ophthalmology ,Physical medicine and rehabilitation ,Injury prevention ,medicine ,Pupillary light reflex ,business - Published
- 2020
5. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment
- Author
-
John A. Wells, Wesley T. Beaulieu, Lee M. Jampol, Susan B. Bressler, Adam R. Glassman, Michele Melia, Kevin J. Blinder, and Neil M. Bressler
- Subjects
medicine.medical_specialty ,Visual acuity ,Randomization ,genetic structures ,Bevacizumab ,business.industry ,Visual impairment ,eye diseases ,law.invention ,Clinical trial ,03 medical and health sciences ,Ophthalmology ,0302 clinical medicine ,Randomized controlled trial ,law ,030221 ophthalmology & optometry ,medicine ,Ranibizumab ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Aflibercept ,medicine.drug - Abstract
Importance Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks of anti–vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment. Objective To assess outcomes of DME persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab. Design, Setting, and Participants Post hoc analyses of a clinical trial, the DRCR.net Protocol T among 546 of 660 participants (82.7%) meeting inclusion criteria for this investigation. Interventions Six monthly intravitreous anti–vascular endothelial growth factor injections (unless success after 3 to 5 injections); subsequent injections or focal/grid laser as needed per protocol to achieve stability. Main Outcomes and Measures Persistent DME through 24 weeks, probability of chronic persistent DME through 2 years, and at least 10-letter (≥ 2-line) gain or loss of visual acuity. Results The mean age of participants was 60 years, 363 (66.5%) were white, and 251 (46.0%) were women. Persistent DME through 24 weeks was more frequent with bevacizumab (118 of 180 [65.6%]) than aflibercept (60 of 190 [31.6%]) or ranibizumab (73 of 176 [41.5%]) (aflibercept vs bevacizumab,P Conclusions and Relevance Persistent DME was more likely with bevacizumab than with aflibercept or ranibizumab. Among eyes with persistent DME, eyes assigned to bevacizumab were more likely to have chronic persistent DME than eyes assigned to aflibercept. These results suggest meaningful gains in vision with little risk of vision loss, regardless of anti–vascular endothelial growth factor agent given or persistence of DME through 2 years. Caution is warranted when considering switching therapies for persistent DME following 3 or more injections; improvements could be owing to continued treatment rather than switching therapies. Trial Registration clinicaltrials.gov Identifier:NCT01627249
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.